Antibodies and Microarrays

Antibodies are important tools in many research and diagnostic applications.
Zedira offers antibodies – polyclonal as well as monoclonal – raised against:

All human transglutaminases

Guinea pig liver transglutaminase

Bacterial transglutaminase

The transglutaminase reaction product: Nε-(γ-glutamyl)-L-lysine-isopeptide bond

Fibrinolytic enzymes: Plasmin and its zymogen (plasminogen)

   Gliadin-variants


Antibody epitope mapping
PEPperPRINT and Zedira commonly present the new PEPperCHIP® Transglutaminase Microarray!
Standard and Custom PEPperCHIP® Peptide Microarrays are synthesized with a unique laser printer based method directly on-chip and are used for e.g. antibody epitope mapping, immunological research, and biomarker discovery.

   Read more about PEPperCHIP® Laser Printing Platform


Antibodies labeled with fluorescent dyes
Zedira provides many of it‘s polyclonal antibodies with a flourescent label like FITC or phycoerythrin or as a biotinylated version. Of course antibodies with other tags are available on demand.

Indirect immuno-staining with A014 Indirect immuno-staining with A014 Indirect immuno-staining with A017

Indirect immuno-stainings
(A) Anti TG2 (A014): mouse colon section (1:100);
(B) Anti TG2 (A014): mouse small intestinal mucosa;
(C) Anti-TG6 (A017): astrocyte in mouse corpus callosum.

(A/B) J. Knauer, Fraunhofer Gesellschaft Leipzig; (C) A. Schulze-Krebs, S. v. Hörsten, University Erlangen


In many applications the need for a fluorescently labeled antibody exists, ranging from fluorescence microscopy to fluorescence-activated cell sorting (FACS).

Transmitted light microscopy FITC-Anti-TG2 with A028 FITC-Anti-TG2 with A027                    
Direct Immuno-Stainings
(A) Transmitted light microscopy, magnification 1:40;
(B) FITC-Anti-TG2 (A028): fluorescence microscopy, magnification 1:40;
(C) FITC-Anti-TG2 (A028): fluorescence microscopy, magnification 1:20.

(A-C) W. Dieterich, University Erlangen-Nürnberg

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland